Marlise Luskin, MD

Quick facts

Phase 3 pipeline

• ABL001 · Oncology
  ABL001 is an allosteric inhibitor of BCR-ABL that binds to a pocket distinct from the ATP-binding site, allowing it to overcome certain resistance mutations.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Marlise Luskin, MD portfolio CI brief
• Marlise Luskin, MD pipeline updates RSS